Phase Ib Study of Chiauranib in Patients With Ovarian Cancer
Status:
Completed
Trial end date:
2019-03-20
Target enrollment:
Participant gender:
Summary
Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B（Aurora
B）、VEGFR/PDGFR/c-Kit、CSF-1R targets. This clinical trial is studying the efficacy and safety
of chiauranib(50mg，QD，PO) works in treating patients with relapsed or refractory ovarian
cancer, in the meantime, exploring the latent biomarkers accompany with chiauranib, as well
as the relevancy of which and clinical benefit.